Angelo Di Leo

Summary

Country: Italy

Publications

  1. pmc Role of lapatinib in the first-line treatment of patients with metastatic breast cancer
    Catherine Oakman
    Sandro Pitigliani Medical Oncology Unit, Hospital of Prato, Istituto Toscano Tumori, Piazza Ospedale 2, 59100, Prato, Italy
    Cancer Manag Res 2:13-25. 2010
  2. doi Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial
    Angelo Di Leo
    Affiliations of authors Sandra Pitigliani Medical Oncology Unit, Hospital of Prato, Prato, Italy ADL, LM Medical Oncology, Centre Hospitalier Universitaire Sart Tilman and Liège University, Liege, Belgium GJ Department of Oncology, First Faculty of Medicine of Charles University, Prague, Czech Republic LP Clinical Oncology, Instituto Nacional del Cancer, Santiago, Chile RT Dnipropetrovsk Municipal Clinical Hospital, Dnipropetrovsk, Ukraine INB Republican Clinical Oncological Center, Kazan, Russia RK AZ Klina, Brasschaat, Belgium DV Mastology, Hospital Nossa Senhora da Conceicao, Porto Alegre, Brazil JLP Thoracal Department, Medical Radiological Science Center, Obninsk, Russia IS Chemotherapy and Combined Therapy, Russian Cancer Research Centre, Moscow, Russia MRL Medical Oncology, Kansas City Cancer Center, Kansas City, MO USA KP AstraZeneca Pharmaceuticals, Macclesfield, UK SG, YR Medical Oncology Service, Instituto de Investigacion Sanitaria, Tokyo
    J Natl Cancer Inst 106:djt337. 2014
  3. pmc Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial
    Lynnette Fernández-Cuesta
    Molecular Carcinogenesis Group, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 8, France
    Breast Cancer Res 14:R70. 2012
  4. pmc Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer
    Angelo Di Leo
    Sandro Pitigliani Medical Oncology Unit, Hospital of Prato, Istituto Toscano Tumori, Prato, Italy 59100
    J Clin Oncol 26:5544-52. 2008
  5. doi HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data
    Angelo Di Leo
    Medical Oncology Unit, Hospital of Prato, Istituto Toscano Tumori, Prato, Italy
    Lancet Oncol 12:1134-42. 2011
  6. doi Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer
    Angelo Di Leo
    Sandro Pitigliani Medical Oncology Unit, Hospital of Prato, Prato, Italy
    J Clin Oncol 28:4594-600. 2010
  7. ncbi p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial
    A Di Leo
    Medical Oncology, Sandro Pitigliani Hospital of Prato, Prato, Italy
    Ann Oncol 18:997-1003. 2007
  8. ncbi Topoisomerase II alpha as a marker predicting anthracyclines' activity in early breast cancer patients: ready for the primetime?
    Angelo Di Leo
    Sandro Pitigliani Medical Oncology Unit, Department of Oncology, Hospital of Prato, Istituto Toscano Tumori, Prato, Italy
    Eur J Cancer 44:2791-8. 2008
  9. doi New strategies to identify molecular markers predicting chemotherapy activity and toxicity in breast cancer
    A Di Leo
    Sandro Pitigliani Medical Oncology Unit, Hospital of Prato, Istituto Toscano Tumori, Prato, Italy
    Ann Oncol 18:xii8-14. 2007
  10. doi The role of topoisomerase IIalpha and HER-2 in predicting sensitivity to anthracyclines in breast cancer patients
    Catherine Oakman
    Translational Research Unit, Department of Oncology, Hospital of Prato, Istituto Toscano Tumori, Piazza Ospedale 2, 59100 Prato, Italy
    Cancer Treat Rev 35:662-7. 2009

Detail Information

Publications50

  1. pmc Role of lapatinib in the first-line treatment of patients with metastatic breast cancer
    Catherine Oakman
    Sandro Pitigliani Medical Oncology Unit, Hospital of Prato, Istituto Toscano Tumori, Piazza Ospedale 2, 59100, Prato, Italy
    Cancer Manag Res 2:13-25. 2010
    ..The role of lapatinib in HER2-negative disease is unclear...
  2. doi Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial
    Angelo Di Leo
    Affiliations of authors Sandra Pitigliani Medical Oncology Unit, Hospital of Prato, Prato, Italy ADL, LM Medical Oncology, Centre Hospitalier Universitaire Sart Tilman and Liège University, Liege, Belgium GJ Department of Oncology, First Faculty of Medicine of Charles University, Prague, Czech Republic LP Clinical Oncology, Instituto Nacional del Cancer, Santiago, Chile RT Dnipropetrovsk Municipal Clinical Hospital, Dnipropetrovsk, Ukraine INB Republican Clinical Oncological Center, Kazan, Russia RK AZ Klina, Brasschaat, Belgium DV Mastology, Hospital Nossa Senhora da Conceicao, Porto Alegre, Brazil JLP Thoracal Department, Medical Radiological Science Center, Obninsk, Russia IS Chemotherapy and Combined Therapy, Russian Cancer Research Centre, Moscow, Russia MRL Medical Oncology, Kansas City Cancer Center, Kansas City, MO USA KP AstraZeneca Pharmaceuticals, Macclesfield, UK SG, YR Medical Oncology Service, Instituto de Investigacion Sanitaria, Tokyo
    J Natl Cancer Inst 106:djt337. 2014
    ..A final analysis of OS was subsequently planned for when 75% of patients had died...
  3. pmc Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial
    Lynnette Fernández-Cuesta
    Molecular Carcinogenesis Group, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 8, France
    Breast Cancer Res 14:R70. 2012
    ....
  4. pmc Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer
    Angelo Di Leo
    Sandro Pitigliani Medical Oncology Unit, Hospital of Prato, Istituto Toscano Tumori, Prato, Italy 59100
    J Clin Oncol 26:5544-52. 2008
    ..This phase III trial evaluated the efficacy of lapatinib in HER-2-negative and HER-2-uncharacterized MBC...
  5. doi HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data
    Angelo Di Leo
    Medical Oncology Unit, Hospital of Prato, Istituto Toscano Tumori, Prato, Italy
    Lancet Oncol 12:1134-42. 2011
    ..We aimed to assess the value of HER2 and TOP2A as predictive markers of response to anthracycline-based adjuvant therapy in patients with early breast cancer...
  6. doi Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer
    Angelo Di Leo
    Sandro Pitigliani Medical Oncology Unit, Hospital of Prato, Prato, Italy
    J Clin Oncol 28:4594-600. 2010
    ....
  7. ncbi p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial
    A Di Leo
    Medical Oncology, Sandro Pitigliani Hospital of Prato, Prato, Italy
    Ann Oncol 18:997-1003. 2007
    ..Preclinical data indicate that p-53 gene mutations predict resistance to doxorubicin (A) but not to docetaxel (Taxotere) (T). In the TAX 303 trial, A and T have been compared with advanced breast cancer patients...
  8. ncbi Topoisomerase II alpha as a marker predicting anthracyclines' activity in early breast cancer patients: ready for the primetime?
    Angelo Di Leo
    Sandro Pitigliani Medical Oncology Unit, Department of Oncology, Hospital of Prato, Istituto Toscano Tumori, Prato, Italy
    Eur J Cancer 44:2791-8. 2008
    ..This manuscript reviews and discusses results from randomised clinical studies evaluating topoisomerase II alpha (topo II) as a marker predicting anthracyclines' activity in early breast cancer patients...
  9. doi New strategies to identify molecular markers predicting chemotherapy activity and toxicity in breast cancer
    A Di Leo
    Sandro Pitigliani Medical Oncology Unit, Hospital of Prato, Istituto Toscano Tumori, Prato, Italy
    Ann Oncol 18:xii8-14. 2007
    ..Ongoing studies should help to answer important questions relating to the use of metabolomics and CTC evaluation as new strategies to monitor cancer progression and identify markers of chemotherapy activity and toxicity...
  10. doi The role of topoisomerase IIalpha and HER-2 in predicting sensitivity to anthracyclines in breast cancer patients
    Catherine Oakman
    Translational Research Unit, Department of Oncology, Hospital of Prato, Istituto Toscano Tumori, Piazza Ospedale 2, 59100 Prato, Italy
    Cancer Treat Rev 35:662-7. 2009
    ....
  11. doi Adjuvant chemotherapy--the dark side of clinical trials. Have we learnt more?
    Catherine Oakman
    Sandro Pitigliani Medical Oncology Unit, Department of Oncology, Hospital of Prato, Tuscany Cancer Institute, Prato, Italy
    Breast 18:S18-24. 2009
    ..The basal phenotype may be predictive of benefit from DNA damaging agents...
  12. ncbi The continued evidence from overviews: what is the clinical utility?
    Natalie Turner
    Sandro Pitigliani Medical Oncology Unit, Department of Oncology, Hospital of Prato, Istituto Toscano Tumori, Prato, Italy
    Breast 22:S8-11. 2013
    ..With these considerations, the Overview has become less clinically relevant as a tool for guiding adjuvant chemotherapy treatment decisions, and a new direction is required. ..
  13. doi Predicting anthracycline benefit: have we made any progress?
    Erica Moretti
    Sandro Pitigliani Medical Oncology Unit, Department of Oncology, Hospital of Prato, Istituto Toscano Tumori, Prato, Italy
    Curr Opin Oncol 21:507-15. 2009
    ..Identification of the individuals to derive this benefit may be guided by predictive biomarkers. This review focuses on the search for biomarkers, particularly focusing on the potential roles for HER-2 and/or topoisomerase IIalpha...
  14. doi Adjuvant systemic treatment for individual patients with triple negative breast cancer
    Catherine Oakman
    Sandro Pitigliani Medical Oncology Unit, Department of Oncology, Hospital ofPrato, Istituto Toscano Tumori, Piazza Ospedale 2, 59100 Prato, Italy
    Breast 20:S135-41. 2011
    ..This review will focus on systemic chemotherapy in early TNBC, particularly anthracyclines and platinums, and potential predictive tools to guide chemotherapy use...
  15. doi Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients
    Marta Pestrin
    Translational Research Unit c o Department of Oncology, Hospital of Prato, Istituto Toscano Tumori, Piazza dell Ospedale 2, 59100, Prato, Italy
    Breast Cancer Res Treat 118:523-30. 2009
    ..278). Our study suggests that a subset of patients with HER2-negative primary tumors develops HER2-positive CTCs during disease progression...
  16. doi Inter- and intra-tumoral heterogeneity in DNA damage evaluated by comet assay in early breast cancer patients
    Francesca Galardi
    Translational Research Unit, Department of Oncology, Hospital of Prato, Istituto Toscano Tumori, Prato, Italy
    Breast 21:336-42. 2012
    ..Comet assay warrants further study as a potential clinical tool for identification of tumoral DNA damage and ultimately, individualised use of DNA damaging therapy...
  17. doi Fulvestrant in the management of postmenopausal women with advanced, endocrine-responsive breast cancer
    Catherine Oakman
    Sandro Pitigliani Medical Oncology Unit, Hospital of Prato, Istituto Toscano Tumori, Piazza Ospedale 2, Prato, Italy
    Future Oncol 7:173-86. 2011
    ..A key issue is identification of patients with ER-positive disease who retain sensitivity to antiestrogen therapy after progression on tamoxifen and/or aromatase inhibitors...
  18. ncbi TOP2A protein by quantitative immunofluorescence as a predictor of response to epirubicin in the neoadjuvant treatment of breast cancer
    Erica Moretti
    Sandro Pitigliani Medical Oncology Unit, Hospital of Prato, Istituto Toscano Tumori, Piazza Ospedale 2, 59100, Prato, Italy
    Future Oncol 9:1477-87. 2013
    ..Anthracyclines are commonly used in breast cancer, although they lack validated predictive biomarkers. We explored the interaction between TOP2A protein by quantitative immunofluorescence (QIF) and anthracycline sensitivity...
  19. ncbi Using specific cytotoxics with a targeted mind
    Angelo Di Leo
    Sandro Pitigliani Medical Oncology Unit, Department of Oncology, Hospital of Prato, Tuscany Cancer Institute, Prato, Italy
    Breast 16:S120-6. 2007
    ..This "targeted" approach to chemotherapy might ultimately lead to a more effective strategy in breast cancer medical treatment...
  20. ncbi Selection of chemotherapeutic drugs in adjuvant programs based on molecular profiles: where do we stand?
    Laura Biganzoli
    Sandro Pitigliani Medical Oncology Unit, Department of Oncology, Hospital of Prato, Piazza dell Ospedale 2, 59100 Prato, Italy
    Crit Rev Oncol Hematol 62:1-8. 2007
    ....
  21. pmc Recent advances in systemic therapy: new diagnostics and biological predictors of outcome in early breast cancer
    Catherine Oakman
    Sandro Pitigliani Medical Oncology Unit, Hospital of Prato, Istituto Toscano Tumori, Prato, Italy
    Breast Cancer Res 11:205. 2009
    ..Extensive research continues on predictive gene identification for specific chemotherapeutic agents, particularly the anthracyclines, taxanes and alkylating agents...
  22. doi Adjuvant chemotherapy: which patient? What regimen?
    Natalie Turner
    From the Sandro Pitigliani Medical Oncology Department, Hospital of Prato, Istituto Toscano Tumori, Prato, Italy Translational Research Unit, Department of Medical Oncology, Hospital of Prato, Istituto Toscano Tumori, Prato, Italy
    Am Soc Clin Oncol Educ Book 33:3-8. 2013
    ..For this, consideration must be given to the combination of underlying tumor biology, tumor stage, and patient characteristics, such as age and tolerability of side effects. ..
  23. doi Management of triple negative breast cancer
    Catherine Oakman
    Sandro Pitigliani Medical Oncology Unit, Department of Oncology, Hospital of Prato, Istituto Toscano Tumori, Piazza Ospedale 2, Prato, Italy
    Breast 19:312-21. 2010
    ..Critical to optimal future management are accurate identification of truly triple negative disease and adequately powered prospective TNBC trials to establish treatment efficacy and define predictive biomarkers...
  24. doi Breast cancer assessment tools and optimizing adjuvant therapy
    Catherine Oakman
    Sandro Pitigliani Medical Oncology Unit, Department of Oncology, Hospital of Prato, Istituto Toscano Tumori, Piazza Ospedale 2, 59100 Prato, Italy
    Nat Rev Clin Oncol 7:725-32. 2010
    ..The presence of drug targets and targetable signaling pathways, rather than molecularly defined subgroups, may ultimately drive treatment decisions...
  25. doi Taxanes in the elderly: can we gain as much and be less toxic?
    Laura Biganzoli
    Sandro Pitigliani Medical Oncology Unit, Department of Oncology, Hospital of Prato, Tuscany Cancer Institute, Piazza dell Ospedale 2, 59100 Prato, Italy
    Crit Rev Oncol Hematol 70:262-71. 2009
    ..e. docetaxel and paclitaxel in elderly patients with the aim to increase their therapeutic index. In addition, recent data on the role of nanoparticle albumine-bound paclitaxel in breast cancer are discussed in this paper...
  26. ncbi Chemotherapy for metastatic breast cancer
    Laura Biganzoli
    Sandro Pitigliani Medical Oncology Unit, Department of Oncology, Prato Hospital, Prato, Italy
    Curr Opin Obstet Gynecol 16:37-41. 2004
    ..This review is intended to summarize the most up-to-date information in the field of chemotherapy for advanced breast cancer...
  27. doi Uncovering the metabolomic fingerprint of breast cancer
    Catherine Oakman
    Department of Oncology, Hospital of Prato, Istituto Toscano Tumori, Prato, Italy
    Int J Biochem Cell Biol 43:1010-20. 2011
    ..The dominant metabolic pathways and metabolite disturbances associated with malignant transformation of breast cells will be outlined, leading to an overview of potential clinical implications for individuals with breast cancer...
  28. ncbi Metabolomics: available results, current research projects in breast cancer, and future applications
    Wederson Marcos Claudino
    Sandro Pitigliani Medical Oncology Unit, Hospital of Prato, Prato, Italy
    J Clin Oncol 25:2840-6. 2007
    ..In the last section, research projects ongoing at our institution and future challenges for metabolomics will be presented and briefly discussed...
  29. ncbi Clinical decision making in breast cancer: TAM and aromatase inhibitors for older patients -- a jungle?
    Laura Biganzoli
    Sandro Pitigliani Medical Oncology Unit, Hospital of Prato, Tuscany Cancer Institute, Piazza dell Ospedale, 59100 Prato, Italy
    Eur J Cancer 43:2270-8. 2007
    ..Longer follow-up of already published trials and additional data coming from ongoing studies will better define when and how to use AIs in the adjuvant setting...
  30. doi Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study
    Marta Pestrin
    Medical Oncology Unit, Hospital of Prato, Prato, Italy
    Breast Cancer Res Treat 134:283-9. 2012
    ..However, considering that only 1/139 screened patients may potentially have derived benefit from this approach, future trials designed according to the presented strategy cannot be recommended...
  31. ncbi HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel
    A Di Leo
    Jules Bordet Institute, Brussels, UK
    Breast Cancer Res Treat 86:197-206. 2004
    ..To evaluate the predictive value of HER-2 in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin (A) or with single-agent docetaxel (T)...
  32. pmc DNA repair gene patterns as prognostic and predictive factors in molecular breast cancer subtypes
    Libero Santarpia
    Translational Research Unit, Department of Oncology, Istituto Toscano Tumori, Prato, Italy
    Oncologist 18:1063-73. 2013
    ..In genes expressed in a bimodal fashion, RECQL4 was significantly associated with clinical outcome. In vitro studies showed that defects in RECQL4 impair homologous recombination, sensitizing BC cells to DNA-damaging agents. ..
  33. ncbi Extensive deep vein thrombosis as a complication of testicular cancer treated with the BEP protocol (bleomycin, etoposide and cisplatin): case report
    Max Senna Mano
    Hospital Nossa Senhora da Conceicao, Porto Alegre, Rio Grande do Sul, Brazil
    Sao Paulo Med J 124:343-5. 2006
    ..There are no reports in the literature of massive deep venous thrombosis (DVT) associated with cisplatin, bleomycin and etoposide (BEP) cancer treatment...
  34. ncbi Gastric cancer metastatic to the pituitary gland: a case report
    Daniele Pozzessere
    Sandro Pitigliani Medical Oncology Unit, Department of Oncology, Misericordia e Dolce Hospital, Prato, Italy
    Tumori 93:217-9. 2007
    ..After diagnosis the patient began thyroid and adrenal-replacement therapy and was referred to Radiotherapy Unit for treatment on the sellar and pituitary gland region...
  35. doi HER2 discordance between primary and metastatic breast cancer: assessing the clinical impact
    Natalie H Turner
    Sandro Pitigliani Medical Oncology Department, Hospital of Prato, Istituto Toscano Tumori, Prato, Italy
    Cancer Treat Rev 39:947-57. 2013
    ..However, whether this is an appropriate recommendation is uncertain, particularly as the clinical implications for HER2 discordance are unknown...
  36. doi Targeting triple negative breast cancer: is p53 the answer?
    Natalie Turner
    Sandro Pitigliani Medical Oncology Unit, Department of Oncology, Hospital of Prato, Prato, Italy
    Cancer Treat Rev 39:541-50. 2013
    ..Within this review, several agents with potential activity against aberrant p53 signaling have been considered, as a novel approach to finding an effective targeted therapy for this aggressive breast cancer subtype...
  37. pmc Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers
    Libero Santarpia
    Department of Oncology, Translational Research Unit, Hospital of Prato and Istituto Toscano Tumori, 59100, Prato, Italy
    Breast Cancer Res Treat 134:333-43. 2012
    ..Simultaneous testing of many different mutations in a single needle biopsy is feasible and allows the design of prospective clinical trials that could test the functional importance of these mutations in the future...
  38. ncbi Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer
    S Chan
    City Hospital, Nottingham, UK
    Ann Oncol 15:1527-34. 2004
    ..To ascertain the efficacy and tolerability of non-pegylated liposomal doxorubicin (Myocet) and epirubicin combined with cyclophosphamide in the first-line treatment of patients with metastatic breast cancer...
  39. ncbi Recombinant truncated dystrophin minigenes: construction, expression, and adenoviral delivery
    P R Clemens
    Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA
    Hum Gene Ther 6:1477-85. 1995
    ..In vivo, recombinant dystrophin was properly localized to the muscle membrane...
  40. ncbi Detection of circulating uroplakin-positive cells in patients with transitional cell carcinoma of the bladder
    S M Li
    Department of Urology, Kaplan Comprehensive Cancer Center, New York University Medical School, and the Veteran Affairs Medical Center in Manhattan, New York 10016, USA
    J Urol 162:931-5. 1999
    ..Detection of uroplakin-positive cells in the circulation would be a strong indication of hematogenous dissemination of tumor cells in patients with TCC...
  41. pmc A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens
    C N Krasner
    Department of Medical Oncology, Massachusetts General Hospital, Boston, MA, USA
    Br J Cancer 97:1618-24. 2007
    ..Trabectedin is an active treatment, with documented responses in patients with platinum sensitive advanced relapsed ovarian cancer, and has a manageable toxicity profile...
  42. ncbi Single fraction radiotherapy for small superficial carcinoma of the skin
    S Chan
    Department of Clinical Oncology, Nottingham University Hospital NHS Trust, Hucknall Road, Nottingham NG5 1PB, UK
    Clin Oncol (R Coll Radiol) 19:256-9. 2007
    ..To define the optimal dose and maximum tumour size of basal and squamous cell carcinoma of skin that can be treated by single fraction radiotherapy...
  43. ncbi Arzoxifene in breast cancer
    S Chan
    Nottingham City Hospital, Hucknall Road, Nottingham, UK
    Eur J Cancer 38:S55-6. 2002
  44. ncbi Objective tests for upper motor neuron involvement in amyotrophic lateral sclerosis (ALS)
    P Kaufmann
    Eleanor and Lou Gehrig MDA ALS Research Center, Neurologic Institute, Department of Neurology, Columbia University, New York 10032, USA
    Neurology 62:1753-7. 2004
    ..To develop objective markers for upper motor neuron (UMN) involvement in ALS, the value of single-voxel MR spectroscopy (MRS) and transcranial magnetic stimulation (TMS) was studied...
  45. ncbi Effects of erythromycin on Pseudomonas aeruginosa adherence to collagen and morphology in vitro
    K W Tsang
    Dept of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong SAR, China
    Eur Respir J 21:401-6. 2003
    ..Therefore, this could help explain the clinical efficacy of low-dose erythromycin therapy on patients with Pseudomonas aeoruginosa infection...
  46. ncbi Bilateral avascular necrosis of the hips after chemoradiotherapy for cervical cancer
    A S Dhadda
    Clin Oncol (R Coll Radiol) 18:576-7. 2006
  47. pmc Bone metastases from breast carcinoma: histopathological - radiological correlations and prognostic features
    J J James
    Nottingham City Hospital, Hucknall Road, Nottingham NG5 1PB, UK
    Br J Cancer 89:660-5. 2003
    ....
  48. pmc SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel-irinotecan as first-line therapy for ovarian cancer
    A R Clamp
    Cancer Research UK Department of Medical Oncology, Christie Hospital, Manchester M20 4BX, UK
    Br J Cancer 94:55-61. 2006
    ..Further exploratory studies of topoisomerase-I inhibitors in this setting may be warranted...
  49. ncbi Phase II study of oral capecitabine in patients with hormone-refractory prostate cancer
    J Spicer
    Division of Oncology, Department of Cellular and Molecular Medicine, St George s Hospital Medical School, Cranmer Terrace, London, UK
    Prostate Cancer Prostatic Dis 8:364-8. 2005
    ..This phase II study was performed to assess the efficacy of the oral fluoropyrimidine capecitabine in advanced prostate cancer...
  50. pmc Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer
    S Chan
    The City Hospital, Nottingham NG5 1PB, UK
    Br J Cancer 91:1420-4. 2004
    ..The basic structure of the pathway was reviewed in this article, together with results of the clinical studies targeting mTOR for cancer therapy. This is an exciting area for development and poses many challenges to researchers...